Inhibition of apoptotic signaling pathways in cancer cells as a mechanism of chemotherapy resistance

Cancer and Metastasis Reviews

Volumn 17, Issue 2, 1998, Pages 233-239

  Haq, Rizwan ^a   Zanke, Brent ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Apoptosis; Bcl 2; Caspases; Intracellular acidification; Solid tumors; Stress Activated Protein Kinase (SAPK)

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE; PROTEINASE;

APOPTOSIS; BLADDER CARCINOMA; CANCER CELL; CANCER CELL DESTRUCTION; CANCER RESISTANCE; CELL PH; CONTROLLED STUDY; ENZYME DEGRADATION; ENZYME INACTIVATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; HUMANS; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION;

EID: 0031873505     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006075007857     Document Type: Review

References (57)

1. Tannock IF: Experimental Chemotherapy. In: Tannock IF, Hill RP (eds) The Basic Science of Oncology, pp. 338-359, 1992. McGraw-Hill.
2. Wyllie AH, Kerr JF, Currie AR: Cell death: the significance of apoptosis. Int Rev Cytol 68: 251-306, 1980
3. Kaufmann S: Induction of endonucleulytic DNA clavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: A cautionary note. Cancer Res 49: 5870-5878, 1989
4. Hannun YA: Apoptosis and the dilemma of cancer chemotherapy. Blood 89: 1845-1853, 1997
5. Antonakopoulos GN, Darnton SJ, Newman J, Duffy JP, Matthews HR: Effects of chemotherapy on ultrastructure of oesophageal squamous cell carcinoma. Histopath 25: 447-454, 1994
6. Wheeler JA, Stephens LC, Tornos C, Eifel PJ, Ang KK, Milas L, Allen PK, Meyn RJ: ASTRO Research Fellowship; apoptosis as a predictor of tumor response to radiation in stage IB cervical carcinoma. Int J Rad Oncol Biol Phys 32: 1487-1493, 1995
7. Tsumimoto Y, Cossman J, Jaffe E, Croce CM: Involvement of the bcl-2 gene in human follicular lymphoma. Science 228: 1440-1443, 1985
8. Rao L, Debbas M, Sabbatini P, Hockenbery D, Korsmeyer S, White E: The adenovirus E1A proteins induce apoptosis, which is inhibited by the E1B 19-kDa and Bcl-2 proteins. Proc Natl Acad Sci USA 89: 7742-7746, 1992
9. Kane DJ, Sarafian TA, Anton R, Hahn H, Gralla EB, Valentine JS, Ord T, Bredesen DE: Bcl-2 inhibition of neural death: decreased generation of reactive oxygen species. Science 262: 1274-1277, 1993
10. Kamesaki S, Kamesaki H, Jorgensen TJ, Tanizawa A, Pommier Y, Cossman J: bcl-2 protein inhibits etoposide-induced apoptosis through its effects on events subsequent to topoisomerase II-induced DNA strand breaks and their repair. Cancer Res 53: 4251-4256, 1993
11. Fairgairn LJ, Cowling GJ, Dexter TM, Rafferty JA, Margison GP, Reipert B: Bcl-2 delay of alkylating agent-induced apoptotic death in a murine hemopoietic stem cell line. Mol Carcinogen 11: 49, 1994
12. Miyashita T, Reed JC: Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 81: 151-157, 1993
13. Kitada S, Takayama S, De RK, Tanaka S, Reed JC: Reversal of chemoresistance of lyniphoma cells by antisense-mediated reduction of bcl-2 gene expression. Antisense Res Dev 4: 71-79, 1994
14. Coustan-Smith E, Kitanaka A, Pui CH, McNinch L, Evans WE, Raimondi SC, Behm FG, Arico M, Campana D: Clinical relevance of BCL-2 overexpression in childhood acute lymphoblastic leukemia. Blood 87: 1140-1146, 1996
15. Hermine O, Haioun C, Lepage E, d'Agay MF, Briere J, Lavignac C, Fillet G, Salles G, Marolleau JP, Diebold J, Reyas F, Gaulard P: Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lyniphoma. Groupe d'Etude des Lymphonies de l'Adulte (GELA). Blood 87: 265-272, 1996
16. Dole MG, Jasty R, Cooper MJ, Thompson CB, Nunez G, Castle VP: Bcl-xL is expressed in neuroblastoma cells and modulates chemotherapy-induced apoptosis. Cancer Res 55: 2576-2582, 1995
17. Sumantran VN, Ealovega MW, Nunez G, Clarke MF, Wicha MS: Overexpression of Bcl-Xs sensitizes MCF-7 cells to chemotherapy-induced apoptosis. Cancer Res 55: 2507, 1995
18. Simonian PL, Grillot DA, Nunez G: Bcl-2 and Bcl-XL can differentially block chemotherapy-induced cell death. Blood 90: 1208-1216, 1997
19. Krajewski S, Blomqvist C, Franssila K, Krajewska M, Wasenius VM, Niskanen E, Nordling S, Reed JC: Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res 55: 4471-4478, 1995
20. Oltvai ZN, Milliman CL, Korsmeyer SJ: Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74: 609-619, 1993
21. Greenblatt MS, Bennett WP, Hollstein M, Harris CC: Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855-4878, 1994
22. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T: p53 is required for radiation induced apoptosis in mouse thymocytes. Nature 362: 847-849, 1993
23. Lowe SW, Ruley HE, Jacks T, Housman DE:p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967, 1993
24. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T: p53 status and the efficacy of cancer therapy in vivo. Science 266: 807-810, 1994
25. Wattel E, Preudhomme C, Hecquet B, Vanrumbeke M, Quesnel B, Dervite I, Morel P, Fenaux P: p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignacies. Blood 84: 3148-3157, 1994
26. Bedi A, Zehnbauer BA, Barber JP, Sharkis SJ, Jones RJ: Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood 83: 2038-2044, 1994
27. Nooter K, Boersma AW, Oostrum RG, Burger H, Jochemsen AG, Stoter G: Constitutive expression of the c-H-ras oncogene inhibits doxorubicin-induced apoptosis and promotes cell survival in a rhahdomyosarcoma cell line. Br J Cancer 71: 556-561, 1995
28. Davis RJ: The mitogen-activated protein kinase signal transduction pathway. J Biol Chem 268: 14553-14556, 1993
29. Crews CM, Erikson RL: Purification of a murine protein-tyrosine/threonine kinase that phosphorylates and activates the Erk-1 gene product: relationship to the fission yeast byr1 gene product. Proc Natl Acad Sci USA 89: 8205-8209, 1992
30. Xia A, Dickens M, Raingeaud J, Davis RJ, Greenberg ME: Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270: 1326-1331, 1996
31. Sun H, Tonks NK, Bar-Sagi D: Inhibition of Ras-induced DNA synthesis by expression of the phosphalase MKP-1. Science 266: 285-288, 1994
32. Minden A, Lin A, Smeal T, Derijard B, Cobb M, Davis R, Karin M: c-Jun N-terminal phosphorylation correlates with activation of the JNK subgroup but not the ERK subgroup of mitogen-activated protein kinases. Mol Cell Biol 14: 6683-6688, 1994
33. Zanke BW, Rubie EA, Boudreau K, McGinnis M, Yan M, Templeton DJ, Woodgett JR: Insulation of mammalian MAP kinase pathways through formation of specific kinase:activator complexes. J Biol Chem 271: 29876-29881, 1996
34. Derijard B, Hibi M, Wu IH, Barrett T, Su B, Deng T, Karin M, Davis RJ: JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell 76: 1025-1037, 1994
35. Freshney NW, Rawlinson L, Guesdon F, Jones E, Cowley S, Hsuan J, Saklatvala J: Interleukin-1 activates a novel protein kinase cascade that results in the phosphorylation of Hsp27. Cell 78: 1039-1049, 1994
36. Seimiya H, Mashima T, Toho M, Tsuruo T: c-Jun NH2-terminal kinase-mediated activation of interleukin-1beta converting enzyme/CED-3-like protease during anticancer drug-induced apoptosis. J Biol Chem 272: 4631-4636, 1997
37. Osborn MT, Chambers TC: Role of the stress-activated/c-Jun NH2-terminal protein kinase pathway in the cellular response to adriamycin and other chemotherapeutic drugs. J Biol Chem 271: 30950-30955, 1996
38. Derijard B, Raingeaud J, Barrett T, Wu IH, Han J, Ulevitch RJ, Davis RJ: Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms. Science 267: 682-685, 1995
39. Sanchez I, Hughes RT, Mayer BJ, Yee K, Woodgett JR, Avruch J, Kyriakis JM, Zon LI: Role of SAPK/ERK kinase-1 in the stress-activated pathway regulating transcription factor c-Jun. Nature 372: 794-798, 1994
40. Lees-Miller SP, Chen YR, Anderson CW: Human cells contain a DNA-activated protein kinase that phosphorylates simian virus 40 T antigen, mouse p53, and the human Ku autoantigen. Mol Cell Biol 10: 6472-6481, 1990
41. Kharbanda S, Ren R, Pandey P, Shafman TD, Feller SM, Weichselbaum RR, Kufe DW: Activation of the c-Abl tyrosine kinase in the stress response to DNA-damaging agents. Nature 376: 785-788, 1995
42. Kharbanda S, Pandey P, Ren R, Mayer B, Zon L, Kufe D: c-Abl activation regulates induction of the SEK1/stress-activated protein kinase pathway in the cellular response to 1-beta-D-arabinofuranosylcytosine. J Biol Chem 270: 30278-30281, 1995
43. Landry J, Huot J: Modulation of actin dynamics during stress and physiological stimulation by a signaling pathway involving p38 MAP kinase and heat-shock protein 27. Biochem Cell Biol 73: 703-707, 1995
44. Guay J, Lambert H, Gingras-Breton G, Lavoie JN, Huot J, Landry J: Regulation of actin filament dynamics by p38 map kinase-mediated phosphorylation of heat shock protein 27. J Cell Sci 110: 357-368, 1997
45. Zanke BW, Boudreau K, Rubie E, Winnett E, Tibbies LA, Zon LI, Kyriakis JM, Liu F-F, Woodgett JR: The stress-activated protein kinase pathway mediates cell death following injury induced by cis-platinum, UV radiation or heat. Curr Biol 6: 606-613, 1996
46. Chen YR, Meyer CF, Tan TH: Persistent activation of c-Jun N terminal kinase 1 (JNK1) in gamma radiation induced apoptosis. J Biol Chem 271: 631-634, 1996
47. Zanke BW, Lee C, Arab SA, Tannock IF: Death of tumor cells after intracellular acidification is dependent on SAPK (JNK) activation and can not be inhibited by BCL-2 expression or ICE inhibition. Cancer Res (in press), 1998
48. Maroney AC, Glicksman MA, Basma AN, Walton KM, Knight E, Murphy CA, Barlett BA, Finn JP, Angeles T, Matsuda Y, Neff NT, Dionne CA: Moroneuron apoptosis is blocked by CEP-1347 (KT 7515), a novel inhibitor of the JNK signaling pathway. J Neurosci 18: 104-111, 1998
49. Yang DD, Kuan C-Y, Whitmarsh AJ, Rincon M, Zheng TS, Davis RJ, Rakic P, Flavell R: Absence of acxitotoxicity-induced apoptosis in the hippocampus of mice lucking the JNK3 gene. Nature 389: 865-870, 1997
50. Seimiya H, Mashima T, Toho M, Tsuruo T: c-Jun NH2-terminal kinase-mediated activation of interleukin-1 beta converting enzyme/CED-3-like protease during anticancer drug-induced apoptosis. J Biol Chem 272: 4631-4636, 1997
51. Verheij M, Bose R, Lin XH, Yao B, Jarvis WD, Grant S, Birrer MJ, Szabo E, Zon LI, Kyriakis JM, Haimovitz-Friedman A, Fuks Z, Kolesnick RN: Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis. Nature 380: 75-79, 1996
52. Chen G, Shu J, Stacey DW: Oncogenic transformation potentiates apoptosis, S-phase arrest and stress-kinase activation by etoposide. Oncogene 15: 1643-1651, 1997
53. Park DS, Stefanis L, Yan CYI, Farinelli SE, Greene LA: Ordering the cell death pathway. J Biol Chem 271: 21898-21905, 1997
54. Maundrell K, Antonsson B, Magnenat E, Camps M, Muda M, Chabert C, Gillieron C, Boschert U, Vial-Knecht E, Martinou JC, Arkinstall S: Bcl-2 undergoes phosphorylation by c-Jun N-terminal kinase/stress-activated protein kinases in the presence of the constitutively active GTP-binding protein Rac1. J Biol Chem 272: 25238-25242, 1997
55. Cahill MA, Peter ME, Kischkel FC, Chinnaiyan AM, Dixit VM, Krammer PH, Nordheim A: CD95 (APO-1/Fas) induces activation of SAP kinases downstream of ICE-like proteases. Oncogene 13: 2087-2096, 1996
56. Teng DH-F, Perry III WL, Hogan JK, Baumgard M, Bell R, Berry S, Davis T, Frank D, Frye C, Hattier T, Hu R, Jammulapati S, Janecki R, Leavitt A, Mitchell JT, Pero R, Sexton D, Schroeder M, Su P-H, Swedlund B, Kyriakis JM, Avruch J, Bartel P, Wong AKC, Oliphant A, Thomas A, Skolnick MH, Tavtigian SV: Human mitogen-activated protein kinase 4 as a candidate tumor suppressor. Cancer Res 57: 4177-4182, 1997
57. Watanabe T, Tsuge H, Oh-Hara T, Naito M, Tsuruo T: Comparative study on reversal efficacy of SDZ PSC 833, cyclosporin A and verapamil on multidrug resistance in vitro and in vivo. Acta Oncol 34: 235-241, 1995